NCT04908280View on ClinicalTrials.gov

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

May 4, 2022

Primary Completion Date

March 4, 2024

Study Completion Date

March 4, 2024

Conditions

Discoid Lupus Erythematosus

Interventions

DRUG

Ruxolitinib

1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.

Trial Locations (1)

14642

UR Medicine Dermatology College Town, Rochester

Sponsors

Collaborators (1)

Incyte Corporation

All Listed Sponsors

collaborator

Incyte Corporation

INDUSTRY

lead

University of Rochester

OTHER